Impel NeuroPharma has appointed Ellen Lubman to serve as its chief business officer. Lubman comes to the Seattle biotech from Allergan (NYSE: [[ticker:AGN]]), where she was vice president of external science and innovation. Impel develops drugs that can be delivered through the nose to the brain. The company’s lead drug, INP104, is in late-stage testing for acute migraine.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
